Kidney involvement in multiple myeloma can result in kidney failure. Unlike Waldenström macroglobulinaemia, hyperviscosity syndrome is a rare occurrence in multiple myeloma. Timely detection of hyperviscosity syndrome and initiation of plasma exchange to remove paraproteins can significantly alter the clinical course and be potentially lifesaving. We report a case of hospitalized patient with kidney failure due to multiple myeloma not in remission who experienced shortened hemodialysis sessions due to early dialysis filter failure due to hyperviscosity, which was later corrected with plasmapheresis. When confirmation of high levels of serum free light chains (sFLCs) was attempted, sFLC was initially reported as “not detectable.” This false-negative result reflected a laboratory artifact caused by a high abundance of sFLCs, known as antigen excess or hook phenomenon. Manual serial dilutions led to unmasking of markedly elevated κ light chain levels. This case exemplifies that patients with multiple myeloma can exhibit clinically challenging kidney manifestations even after becoming dialysis dependent.

INTRODUCTION

Kidney involvement in patients with multiple myeloma is common. Hyperviscosity syndrome is a severe complication that necessitates emergent plasma exchange for paraprotein removal. Hyperviscosity syndrome, commonly described in Waldenström macroglobulinemia, is less frequently reported in patients with multiple myeloma (2%-6%). The revised International Myeloma Work Group has incorporated serum free light chain (sFLC) ratio as a biomarker in the diagnosis of multiple myeloma. Given their short half-life, sFLCs are clinically useful for monitoring response to therapy. However, sFLC assays could be subject to methodological variations, resulting in spuriously low values. We describe an unusual case of multiple myeloma in a patient with kidney failure dependent on hemodialysis presenting with hyperviscosity syndrome who later exhibited the antigen excess artifact.

CASE REPORT

A women in her mid-50s had multiple myeloma diagnosed 5 months before the index admission. She had an abnormal M band on the gamma portion of serum protein electrophoresis, immunofixation (IFE) gel suggestive of free κ light chain monoclonal protein, diffuse κ free light chains at 2,190 mg/dL on IFE, and κ:λ ratio of 3.696. A bone marrow biopsy specimen revealed 70% to 80% plasma cells and hypercellularity. She subsequently received 2 cycles of bortezomib, cyclophosphamide, and dexamethasone, and 1 cycle of high-dose cyclophosphamide, carfilzomib, and dexamethasone, the last cycle being 1 month before the index admission, without attaining clinical remission. Her kidney function declined and she required kidney replacement therapy. She was declared as having end-stage kidney disease 2 months before the index admission.

The authors were not directly involved in the care of the patient on the previous hospital admission. At that time, the treating physicians opted not to perform a kidney biopsy because it was believed that there was overwhelming clinical evidence to establish a clinical diagnosis of myeloma cast nephropathy (severe oliguric kidney failure and substantially elevated κ free light chains) and the risk for bleeding complications was deemed high (frailty and thrombocytopenia).

In the index admission, the patient presented to the emergency department with confusion and weakness. On examination, she was afebrile and tachycardic, with blood pressure of 150/90 mm Hg. Significant laboratory values included serum albumin level of 1.8 g/L, serum urea nitrogen level of 12 mg/dL, serum creatinine level of 5.1 mg/dL, κ light chain level < 0.04 mg/dL, and λ light chain level of 0.19 mg/dL. Computed tomography of the head and infectious workup were negative, and the patient did not report missing any of her dialysis sessions.

One hour into the patient’s scheduled hemodialysis session, the dialysis filter clotted and the treatment was interrupted. This session was resumed with the addition of a 2,000-unit heparin bolus and saline solution for prefiltro dilution at blood flow rate of 250 mL/min, dialysate flow rate of 700 mL/min, and an F160 membrane (Fresenius Optiflux). However, the filter clotted again several times (once after 8 minutes and again after 15 minutes). Extremely elevated transmembrane pressure was recorded despite the administration of perceived adequate anticoagulation. Serum viscosity was then measured and found to be profoundly elevated at 7.88 centipoise (cP) (normal, 1.1-1.3 cP). A diagnosis of hyperviscosity syndrome was made and emergent plasma exchange was initiated.

At that time, serum protein electrophoresis and IFE reported elevated free κ light chains at 6,380 mg/dL; this contrasted with concurrent sFLCs analyzed by @Freelite
that revealed $\kappa$ light chains $< 0.04$ mg/dL and $\lambda$ of $0.19$ mg/dL, values that did not correlate with other laboratory results or disease severity. This raised suspicion of the antigen excess artifact, or hook phenomenon. We conjointly worked with the clinical laboratory team and performed manual dilutions of 1:1,000 and 1:10,000, which resulted in substantially elevated $\kappa$ light chain levels at 129,910 mg/dL. Her neurologic condition improved moderately after 3 sessions of plasma exchange. Unfortunately, the patient could not tolerate further rounds of chemotherapy due to side effects and her disease progressed. Multidisciplinary team discussions were held and the patient opted for hospice care.

DISCUSSION

Our case illustrates 2 important and relatively underappreciated concepts in the management of multiple myeloma. First, the phenomenon of hyperviscosity syndrome. Lambda free light chains exist as dimers with molecular weight of 45 kDa, as compared with $\kappa$ light chains which exist as monomers with molecular weight of 22.5 kDa. As glomerular filtration rate declines, kidney clearance of sFLCs decreases and therefore the potential for light chain accumulation is high, with subsequent risk for hyperviscosity syndrome. Additionally, light chain clearance through the reticuloendothelial system is unaffected by the molecular weight of the light chains, such that the serum half-lives of both $\lambda$ and $\kappa$ light chains become similar, leading to an increased median sFLC ratio among patients with kidney failure. Although hyperviscosity syndrome is occasionally reported among patients with multiple myeloma, the presentation of recurrent hemodialysis filter clots secondary to hyperviscosity in a dialysis patient with multiple myeloma makes our case unique.

Timely initiation of plasma exchange to remove paraproteins can significantly alter the clinical course and be potentially lifesaving. The neurological condition of our patient improved moderately after 3 plasma exchange sessions. In addition to correcting hyperviscosity, which was the likely cause of clinical presentation, reduction in free light chain burden helped lower dialysis transmembrane pressures and allowed for successful completion of hemodialysis sessions. This case highlights the importance of considering plasma exchange in...

Figure 1. Algorithm for an approach to patients with multiple myeloma and kidney failure requiring kidney replacement therapy. Abbreviations: chemo, chemotherapy; cP, centipoise.
conjunction with hemodialysis in dialysis-dependent patients with multiple myeloma presenting with hyperviscosity (Fig 1).

The second concept encountered in this case was the coexistence of antigen excess, reported in 1% to 10% of samples from patients with multiple myeloma. This phenomenon is explained by a substantially elevated antigen concentration that exceeds antibody levels, resulting in spuriously low antigen antibody complexes and negative results. The hook phenomenon, as encountered with sFLCs, is synonymous to the prozone effect that is reported with intact immunoglobulins. Our patient had spuriously low reported κ and λ values. This finding likely was secondary to excess κ chain burden, overwhelming the concentration of antibodies and thereby impairing the assay performance. Polyclonal antibodies of the sFLC assay recognize epitopes on the constant region of light chains, which are exposed when light chains remain in free forms. Currently, multiple commercial assays are available for measuring sFLCs: Freelite, an immune nephelometric/turbidimetric assay; N latex FLC assay (Siemens Healthcare Diagnostics), based on monoclonal antibodies; and Sebia FLC, enzyme-linked immunosorbent assay (ELISA) based assays.

Other methodological variations in analyzing sFLC assay include overestimation, which is secondary to polymerization of free light chains, exposing multiple epitopes and thereby generating falsely higher values. Nonlinear variations with a 2-fold or higher difference in sFLC values with various dilutions were reported as well. Lot-to-lot variation of sFLC concentrations of 8% to 45% have been reported with Freelite assay. Automated machine flags and delta checks can be incorporated to alarm unusual values. Sample dilutions, monoclonal antibodies, and more sophisticated modalities such as ELISA-based assays (Sebia FLC) and mass spectrometry help detect antigen excess. Table 1 describes the challenges in analyzing sFLC assays and potential recommendations.

In conclusion, prompt attention should be paid to dialysis-dependent patients with multiple myeloma who exhibit hemodialysis interruptions due to dialysis filter clotting, and have a low threshold to consider hyperviscosity syndrome. Early initiation of plasma exchange could be potentially lifesaving. Additionally, the antigen excess artifact, although rare is encountered in 1% to 10% cases of active multiple myeloma. ELISA-based assays and mass spectrometry are relatively more sophisticated and help mitigate some errors. Careful consideration of clinical context and combined interpretation of various serologic tests, including serum protein electrophoresis, IFE, and sFLC, is advised to guide clinical decision making.

REFERENCES

1. Reue S, Sexton DJ, Solid CA, Chen SC, Foley RN. ESRD due to multiple myeloma in the United States, 2001-2010. J Am Soc Nephrol. 2016;27(5):1487-1494.
2. Mehta J, Singhal S. Hyperviscosity syndrome in plasma cell dyscrasias. Semin Thromb Hemost. 2003;29(5):467-471.
3. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):eS38-eS48.
4. Levinson SS. Hook effect with lambda free light chain in serum free light chain assay. Clin Chim Acta. 2010;411(21-22):1834-1836.
5. Hutchison CA, Harding S, Hewins P, Mead GP, Townsend J, Bradwell AR, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(6):1684-1690.
6. Rassner MP, Seidl M, Salzer U, Rajkumar SV, Epting T, Wäsch R, et al. Cast nephropathy and deceptively low absolute serum free light chain levels: resolution of a challenging case and systematic review of the literature. *Clin Lymphoma Myeloma Leuk*. 2018;18(1):e1-e7.

7. Talamo G, Castellani W, Dolloff NG. Prozone effect of serum IgE levels in a case of plasma cell leukemia. *J Hematol Oncol*. 2010;3(1):32.

8. Kang SY, Suh JT, Lee HJ, Yoon HJ, Lee WI. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma. *Ann Hematol*. 2005;84(9):588-593.

9. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. *Clin Chem*. 2001;47(4):673-675.

10. te Velthuis H, Knop I, Stam P, van den Broek M, Bos HK, Hol S, et al. N Latex FLC - new monoclonal high-performance assays for the determination of free light chain kappa and lambda. *Clin Chem Lab Med*. 2011;49(8):1323-1332.

11. Lutteri L, Aldenhoff M-C, Cavalier E. Evaluation of the new Sebia free light chain assay using the AP22 ELITE instrument. *Clin Chim Acta*. 2018;487:161-167.

12. Abraham RS, Charlesworth MC, Owen BA, Benson LM, Katzmann JA, Reeder CB, et al. Trimolecular complexes of lambda light chain dimers in serum of a patient with multiple myeloma. *Clin Chem*. 2002;48(10):1805-1811.

13. Tate JR, Bazeley S, Sykes S, Mollee P. Quantitative serum free light chain assay–analytical issues. *Clin Biochem Rev*. 2009;30(3):131-140.

14. Tate JR, Mollee P, Dimeski G, Carter AC, Gill D. Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases. *Clin Chim Acta*. 2007;376(1-2):30-36.

15. McCudden CR, Voorhees PM, Hammett-Stabler CA. A case of hook effect in the serum free light chain assay using the Olympus AU400e. *Clin Biochem*. 2009;42(1):121-124.

16. Bosmann M, Kössler J, Stolz H, Walter U, Knop S, Steigerwald U. Detection of serum free light chains: the problem with antigen excess. *Clin Chem Lab Med*. 2010;48(10):1419-1422.

17. Pretorius CJ, Klingberg S, Tate J, Wilgen U, Ungerer JP. Evaluation of the N Latex FLC free light chain assay on the Siemens BN analyser: precision, agreement, linearity and variation between reagent lots. *Ann Clin Biochem*. 2012;49(pt 5):450-455.

18. VanDuijn MM, Jacobs JFM, Wevers RA, Engelke UF, Joosten I, Luider TM. Quantitative measurement of immunoglobulins and free light chains using mass spectrometry. *Anal Chem*. 2015;87(16):8268-8274.

19. Shaheen SP, Levinson SS. Serum free light chain analysis may miss monoclonal light chains that urine immunofixation electrophoreses would detect. *Clin Chim Acta*. 2009;406(1):162-166.

20. Nakano T, Nagata A. ELISAs for free human immunoglobulin light chains in serum: improvement of assay specificity by using two specific antibodies in a sandwich detection method. *J Immunol Methods*. 2004;293(1-2):183-189.